ZBTB32

Across TCGA pan-cancer cohorts, ZBTB32 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBTB32 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ZBTB32 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZBTB32 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

STAD, UCEC, and LIHC are the cancer types where ZBTB32 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	1.000	0.375	.023	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.043	0.527	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZBTB32–STAD (DFS)

Open the STAD breakdown →